MicroDose Therapeutx has dosed its first patient in a Phase I clinical trial of MDT-637, an inhalable antiviral fusion inhibitor designed to treat respiratory syncytial virus.

MDT-637 is formulated for inhaled delivery via MicroDose’s proprietary dry powder nebuliser, a device which allows for the rapid delivery of dry powder medications via tidal inhalation to the site of infection in the respiratory tract.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US-based, single ascending dose, randomised, placebo controlled Phase I trial is intended to evaluate the safety, tolerability and pharmacokinetics of MDT-637 in 48 healthy adult subjects.

The Phase I trial follows the reactivation of the US IND for MDT-637 as re-formulated for delivery using MicroDose’s proprietary dry powder nebuliser.

MicroDose is developing MDT-637 through Phase IIa clinical trials in collaboration with Gilead Sciences.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now